Slawomir Mandziuk
Overview
Explore the profile of Slawomir Mandziuk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Szponar J, Ciechanski E, Ciechanska M, Dudka J, Mandziuk S
Int J Mol Sci
. 2025 Jan;
25(24.
PMID: 39769331
Doxorubicin (DOX) has been widely used as a cytotoxic chemotherapeutic. However, DOX has a number of side effects, such as myelotoxicity or gonadotoxicity, the most dangerous of which is cardiotoxicity....
2.
Rudzinska A, Juchaniuk P, Oberda J, Krukowska K, Krzyskowska S, Kuchta E, et al.
Front Oncol
. 2024 Dec;
14:1459608.
PMID: 39655067
Introduction: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by enhancing T-cell-mediated immune responses against tumors. However, their use can lead to immune-related adverse events (irAEs), impacting patient outcomes. Methods:...
3.
Krukowska K, Krzyskowska S, Kuchta E, Rudzinska A, Szklener K, Mandziuk S
Front Oncol
. 2024 Dec;
14:1450105.
PMID: 39640281
Introduction: In recent years, pain has been recognized as a primary factor significantly diminishing the quality of life in cancer patients. Recent data have prompted the establishment and increased application...
4.
Szczepanski J, Khylyuk D, Korga-Plewko A, Michalczuk M, Mandziuk S, Iwan M, et al.
Int J Mol Sci
. 2024 Nov;
25(22).
PMID: 39596465
Breast cancer is one of the most common malignancies affecting women worldwide, with a significant need for novel therapeutic agents to target specific molecular pathways involved in tumor progression. In...
5.
Bilski M, Szklener K, Szklener S, Rudzinska A, Kluz N, Klas J, et al.
Front Neurol
. 2024 Apr;
15:1370091.
PMID: 38633530
Introduction: Essential tremor (ET) is the most common movement disorder in adults, with an estimated incidence of up to 1% of the population and 5% of people older than 65 ...
6.
Galazka J, Czeczelewski M, Kucharczyk T, Szklener K, Mandziuk S
Arch Med Sci
. 2024 Feb;
20(1):313-316.
PMID: 38414472
Introduction: In this retrospective study, the authors evaluated whether obesity-induced immunomodulation impacts the expression of programmed death ligand-1 (PD-1L) in lung cancer cells.Methods: A retrospective cross-sectional study was performed. The...
7.
Szponar J, Gorska A, Ostrowska-Lesko M, Korga-Plewko A, Tchorz M, Ciechanski E, et al.
Int J Mol Sci
. 2024 Feb;
25(4).
PMID: 38396896
Late cardiotoxicity is a formidable challenge in anthracycline-based anticancer treatments. Previous research hypothesized that co-administration of carvedilol (CVD) and dexrazoxane (DEX) might provide superior protection against doxorubicin (DOX)-induced cardiotoxicity compared...
8.
Szklener K, Bilski M, Nieoczym K, Mandziuk D, Mandziuk S
Front Oncol
. 2023 Nov;
13:1274587.
PMID: 37916157
Glioblastoma (GBM) represents a significant therapeutic challenge due to its aggressive nature. Tumor Treating Fields (TTFields) present a promising approach to GBM therapy. The primary mechanism of TTFields, an antimitotic...
9.
Szponar J, Ciechanski E, Ostrowska-Lesko M, Gorska A, Tchorz M, Dabrowska A, et al.
Int J Mol Sci
. 2023 Jun;
24(12).
PMID: 37373350
The anticancer efficacy of doxorubicin (DOX) is dose-limited because of cardiomyopathy, the most significant adverse effect. Initially, cardiotoxicity develops clinically silently, but it eventually appears as dilated cardiomyopathy with a...
10.
Rudzinska A, Juchaniuk P, Oberda J, Wisniewska J, Wojdan W, Szklener K, et al.
Nutrients
. 2023 Apr;
15(8).
PMID: 37111115
Phytochemicals are a non-nutritive substances that are present in plants and contribute significantly to their flavor and color. These biologically active compounds are classified into five major groups, namely phenolics,...